- In April 2024, Know Labs, Inc., a U.S.-based medical technology company, announced the successful completion of clinical validation trials for its Bio-RFID sensor technology. Designed to measure blood glucose levels non-invasively using radiofrequency spectroscopy, the trials demonstrated promising accuracy results, marking a critical step toward FDA submission. This development reflects Know Labs' commitment to transforming diabetes management with painless, real-time glucose monitoring solutions for both clinical and personal use
- In March 2024, DiaMonTech GmbH, a German-based healthtech innovator, secured a new round of funding to accelerate the commercialization of its non-invasive glucose monitoring device, which uses infrared laser-based technology. The company is focused on launching a portable consumer device with clinical-grade accuracy. This milestone signifies increasing investor confidence in non-invasive technologies and supports the broader push toward more accessible, user-friendly glucose monitoring tools in the European market
- In February 2024, Afon Technology, a UK-based medical device company, introduced the prototype of its non-invasive glucose monitoring wearable at the Arab Health 2024 Exhibition in Dubai. The device, designed as a wrist-worn band, continuously monitors glucose without skin penetration and delivers data through a mobile app. This unveiling positions Afon Technology as a key player in the global shift toward connected, non-invasive diabetes management solutions, particularly in emerging and tech-forward markets
- In January 2024, Movano Health, based in California, announced advancements in its smart ring platform that incorporates non-invasive glucose monitoring along with other vital health metrics. The company is targeting both diabetic and non-diabetic users with a holistic wellness approach. This innovation represents the growing convergence of consumer electronics and medical-grade biosensing technologies, aiming to broaden market reach beyond traditional healthcare users
- In December 2023, Apple Inc. reportedly progressed further in its long-term initiative to integrate non-invasive glucose sensing into future Apple Watch models. Leveraging optical absorption spectroscopy, Apple’s prototype efforts reflect the tech industry’s increasing interest in preventive healthcare tools. While still in R&D, this potential integration has captured significant attention and could redefine mainstream adoption of non-invasive glucose monitoring on a global scale
